ストックスクリーナーアプリを入手
2.32
1.28%
-0.03
アフターアワーズ：
2.38
0.06
+2.59%
前日終値:
$2.35
開ける：
$2.36
24時間の取引高:
3.22M
Relative Volume:
0.73
時価総額：
$536.98M
収益：
-
当期純損益:
$-179.82M
株価収益率:
-1.7444
EPS:
-1.33
ネットキャッシュフロー:
$-159.16M
1週間 パフォーマンス:
-4.72%
1か月 パフォーマンス:
-7.94%
6か月 パフォーマンス:
+20.21%
1年 パフォーマンス:
+82.68%
1日の値動き範囲:
$2.27
$2.3795
1週間の範囲:
$2.16
$2.50
52週間の値動き範囲:
$0.76
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.32 | 543.92M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-09-10 | アップグレード | UBS | Neutral → Buy |
| 2025-07-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-05 | 再開されました | Wedbush | Outperform |
| 2023-07-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | JP Morgan | Neutral |
| 2022-09-19 | 開始されました | Wedbush | Outperform |
| 2022-04-18 | 開始されました | Raymond James | Outperform |
| 2022-04-06 | 開始されました | UBS | Buy |
| 2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 再開されました | Piper Sandler | Overweight |
| 2020-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-30 | 開始されました | Berenberg | Buy |
| 2019-03-05 | 開始されました | Barclays | Overweight |
| 2019-03-05 | 開始されました | BofA/Merrill | Buy |
| 2019-03-05 | 開始されました | Evercore ISI | Outperform |
| 2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
Gossamer Bio, Inc. (GOSS): Biotech Stock With A Promising 283% Upside Potential - DirectorsTalk Interviews
Traders Buy High Volume of Gossamer Bio Put Options (NASDAQ:GOSS) - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Shares Up 8.8%Should You Buy? - MarketBeat
Barclays Gives Gossamer Bio Overweight Rating and Bright Outlook - StocksToTrade
Gossamer Bio Sees Unusually Large Options Volume (NASDAQ:GOSS) - MarketBeat
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Is Gossamer Bio Inc forming a breakout pattern2025 Price Action Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Upgraded to "Strong-Buy" at Barclays - MarketBeat
Gossamer Bio (GOSS) Submits Mixed Securities Shelf Filing - GuruFocus
Barclays Initiates Coverage on Gossamer Bio With Overweight Rating, $9 Price Target - marketscreener.com
Barclays Initiates Coverage on Gossamer Bio (GOSS) with Overweig - GuruFocus
Institution Moves: Should I buy Gossamer Bio Inc stock nowTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Earnings Report: Is Gossamer Bio Inc a stock for growth or value investors2025 Performance Recap & Smart Swing Trading Alerts - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.7%Here's Why - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock - Investing.com
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial - Investing.com Nigeria
Gossamer Bio (NASDAQ:GOSS) Given Buy Rating at HC Wainwright - MarketBeat
GOSS: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance
Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Gossamer Bio Inc Just Went Wild: Is This Tiny Biotech the Next Viral Moonshot or Total Trap? - AD HOC NEWS
Aug Spikes: How does Napco Security Technologies Inc score in quality rankingsTrade Volume Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Pullback Watch: What are the risks of holding ProShares Trust ProShares Short MSCI Emerging MarketsWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is the fair value of Gossamer Bio Inc. stock nowTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Is Gossamer Bio Inc. stock trading at a premium valuation2025 Winners & Losers & High Accuracy Investment Signals - Улправда
Gossamer Bio, Inc. (GOSS): Analyst Ratings Highlight a Significant 294% Upside for Biotech Investors - DirectorsTalk Interviews
How Gossamer Bio Inc. (4GB) stock reacts to stronger dollarTrade Analysis Report & AI Powered Market Entry Ideas - Улправда
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biotech Gossamer Bio gives new hires a stake with long-term stock options - Stock Titan
Can Gossamer Bio Inc. stock hit record highs againJuly 2025 Macro Moves & Weekly Setup with High ROI Potential - Улправда
Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS) - Defense World
Gossamer Bio Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since November 2024 -- Data Talk - 富途牛牛
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):